MA42946A - Sels et formes solides d'un antibiotique de type monobactame - Google Patents

Sels et formes solides d'un antibiotique de type monobactame

Info

Publication number
MA42946A
MA42946A MA42946A MA42946A MA42946A MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A
Authority
MA
Morocco
Prior art keywords
salts
solid forms
monobactam antibiotic
oxo
amino
Prior art date
Application number
MA42946A
Other languages
English (en)
Other versions
MA42946B1 (fr
Inventor
Eric Aubin
Anthony Casarez
Andreas Fisch
Zaixing Li
Mika Lindvall
Heinz Ernst Moser
Michael Mutz
Folkert Reck
Bernd Ulrich Riebesehl
Marc Schoenhentz
Vijay Sethuraman
Robert Lowell Simmons
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA42946A publication Critical patent/MA42946A/fr
Publication of MA42946B1 publication Critical patent/MA42946B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La fourniture de nouvelles formes solides, des sels et des polymorphes d'acide 1-(((z)-(1-(2-aminothiazol-4-yl)2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidine-3-yl)méthyl)-1-sulfoazetidin-3-yl)amino)éthylidène)amino)oxy)-cyclopropanecarboxylique (désigné ici en tant que composé x), des compositions pharmaceutiques les contenant et des procédés pour leur fabrication et leur utilisation en thérapie.
MA42946A 2015-09-23 2016-09-20 Sels et formes solides d'un antibiotique de type monobactame MA42946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222430P 2015-09-23 2015-09-23
PCT/CN2016/099482 WO2017050218A1 (fr) 2015-09-23 2016-09-20 Sels et formes solides d'antibiotique monobactame

Publications (2)

Publication Number Publication Date
MA42946A true MA42946A (fr) 2018-08-01
MA42946B1 MA42946B1 (fr) 2020-10-28

Family

ID=58385723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42946A MA42946B1 (fr) 2015-09-23 2016-09-20 Sels et formes solides d'un antibiotique de type monobactame

Country Status (25)

Country Link
US (1) US10919887B2 (fr)
EP (1) EP3353175B1 (fr)
JP (1) JP6837480B2 (fr)
KR (1) KR20180054816A (fr)
CN (1) CN108137573B (fr)
AU (1) AU2016327264B2 (fr)
CA (1) CA2999794C (fr)
CL (2) CL2018000745A1 (fr)
CY (1) CY1123509T1 (fr)
DK (1) DK3353175T3 (fr)
EA (2) EA202092620A1 (fr)
ES (1) ES2817537T3 (fr)
HK (1) HK1257271A1 (fr)
HR (1) HRP20201423T1 (fr)
HU (1) HUE050849T2 (fr)
IL (1) IL258254B (fr)
LT (1) LT3353175T (fr)
MA (1) MA42946B1 (fr)
MX (1) MX2018003592A (fr)
PH (1) PH12018500653A1 (fr)
PT (1) PT3353175T (fr)
RS (1) RS60805B1 (fr)
RU (1) RU2754180C2 (fr)
SI (1) SI3353175T1 (fr)
WO (1) WO2017050218A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094281B (zh) * 2017-08-02 2023-08-29 诺华股份有限公司 用于制备单内酰胺抗生素的化学方法及其中间体
US11760866B2 (en) * 2017-08-16 2023-09-19 Lg Chem, Ltd. White pigment comprising ZIF-based powder, polymer resin film and method for changing color of medium using white pigment
WO2019092180A1 (fr) * 2017-11-10 2019-05-16 Novartis Ag Administration de monobactame pour le traitement d'une infection urinaire
CN111511737B (zh) * 2018-01-29 2022-10-18 南京明德新药研发有限公司 用于治疗细菌感染的单环β-内酰胺化合物
US20220062244A1 (en) * 2018-12-18 2022-03-03 Medshine Discovery Inc. APPLICATION OF MONOCYCLIC ß-LACTAM COMPOUND IN PHARMACY
US20230037556A1 (en) * 2019-11-22 2023-02-09 Suzhou Erye Pharmaceutical Co., Ltd SULFONYLUREA RING SUBSTITUTED MONOCYCLIC beta-LACTAM ANTIBIOTICS
EP4079305A4 (fr) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Tech Co Ltd Application d'un composé dans la préparation de médicament
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN114728953B (zh) * 2020-08-06 2024-04-09 宁夏农林科学院 β-内酰胺类化合物，及其制备方法以及其作为抗菌素的应用
WO2022185240A1 (fr) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation d'un antibiotique monobactame
WO2022185241A1 (fr) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Procédé de fabrication d'un antibiotique monobactame
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ205240A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Sulphonamide derivatives,being starting materials for producing beta-lactams
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (fr) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Antibiotiques de bêta-lactame
WO1982001873A1 (fr) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd Derives 1-sulfo-2-oxoazetidine et leur procede de preparation
US4782147A (en) 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
CA1262128A (fr) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
HU189290B (en) 1982-05-31 1986-06-30 Banyu Pharmaceutical Co Ltd,Jp Process for preparing new 2-oxo-1-azetidine-sulphonic acid derivatives and pharmaceutically acceptable salts thereof, further pharmaceutical compositions containing such derivatives as active substances
DE3377061D1 (en) 1982-06-03 1988-07-21 Hoffmann La Roche Process for the preparation of 1-sulfo-2-oxoazetidine derivatives
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd ２−オキソ−１−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
US9238657B2 (en) 2008-10-31 2016-01-19 Shionogi & Co., Ltd. Cephalosporin having catechol group
MX2011006541A (es) * 2008-12-19 2011-07-20 Pfizer Monocarbamas.
SG190007A1 (en) 2010-11-29 2013-06-28 Pfizer Monobactams
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
BR112016020333B1 (pt) * 2014-03-24 2022-08-09 Novartis Ag Compostos orgânicos de monobactam, seus usos, composições e combinações farmacêuticas

Also Published As

Publication number Publication date
US10919887B2 (en) 2021-02-16
LT3353175T (lt) 2020-10-12
EA202092620A1 (ru) 2021-06-30
AU2016327264A1 (en) 2018-05-10
JP6837480B2 (ja) 2021-03-03
MX2018003592A (es) 2018-06-18
EP3353175B1 (fr) 2020-08-12
CL2019003324A1 (es) 2020-04-17
HK1257271A1 (zh) 2019-10-18
RU2018114480A (ru) 2019-10-23
RU2018114480A3 (fr) 2020-06-09
PT3353175T (pt) 2020-09-10
RU2754180C2 (ru) 2021-08-30
CA2999794C (fr) 2023-08-15
AU2016327264B2 (en) 2019-06-27
IL258254A (en) 2018-05-31
US20180273522A1 (en) 2018-09-27
EA201890771A1 (ru) 2018-09-28
DK3353175T3 (da) 2020-09-14
CN108137573A (zh) 2018-06-08
MA42946B1 (fr) 2020-10-28
BR112018005805A2 (pt) 2018-10-16
CL2018000745A1 (es) 2018-06-22
EP3353175A4 (fr) 2019-06-26
WO2017050218A1 (fr) 2017-03-30
EP3353175A1 (fr) 2018-08-01
KR20180054816A (ko) 2018-05-24
JP2018528241A (ja) 2018-09-27
SI3353175T1 (sl) 2020-11-30
CY1123509T1 (el) 2022-03-24
HRP20201423T1 (hr) 2020-12-11
HUE050849T2 (hu) 2021-01-28
IL258254B (en) 2021-02-28
CA2999794A1 (fr) 2017-03-30
PH12018500653A1 (en) 2018-10-01
ES2817537T3 (es) 2021-04-07
CN108137573B (zh) 2021-06-11
EA037569B1 (ru) 2021-04-15
RS60805B1 (sr) 2020-10-30

Similar Documents

Publication Publication Date Title
MA42946A (fr) Sels et formes solides d'un antibiotique de type monobactame
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
BR112018015289A2 (pt) compostos de benzopirazol e análogos dos mesmos
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
AR062980A1 (es) Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida
AR086254A1 (es) Derivados de imidazol utiles para el tratamiento de artritis
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
NZ716421A (en) Drug for treatment of nonalcoholic fatty liver disease
PE20141148A1 (es) Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
BR112020012712A8 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc
BR112022001600A2 (pt) Regimes de dosagem para inibidores do fator d de complemento oral
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
BRPI0909211B8 (pt) formulação oral em forma de comprimido de compostos de tetraciclina
MA54379A (fr) Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant
BRPI0514412A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(gama) ppar(alfa)
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа